PURPOSE: To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma. METHODS: Patients were treated with escalating doses of oblimersen administered by continuous intravenous infusion (CIVI) days 1 to 7, CIVI 5-fluorouracil (5-FU) days 4 to 7, and cisplatin on day 4 every 3 weeks. RESULTS: Fifteen patients received a total of 49 courses of oblimersen at doses of 3, 5, or 7 mg/kg/d given as a 7 day CIVI in combination with 4 or 5 day CIVI of 5-FU (1000 or 750 mg/m2/d) plus intravenous cisplatin (100 or 75 mg/m2 over 2 hours). The recommended phase II dose of oblimersen was 5 mg/kg/d in combination with 5-FU (750 mg/m2/d for 4 days) and cisplatin (75 mg/m). The most common grade 3 to 4 adverse events that occurred in at least 10% of patients at all dose levels included neutropenia (33%), hypokalemia (27%), infection (20%), and mucositis, fatigue, dizziness, thrombosis, and dehydration (in 13% for each category). CONCLUSION: The combination of oblimersen with 5-FU and cisplatin chemotherapy is feasible in patients with advanced upper gastrointestinal cancer, with antitumor activity observed in gastric carcinoma.
PURPOSE: To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma. METHODS:Patients were treated with escalating doses of oblimersen administered by continuous intravenous infusion (CIVI) days 1 to 7, CIVI 5-fluorouracil (5-FU) days 4 to 7, and cisplatin on day 4 every 3 weeks. RESULTS: Fifteen patients received a total of 49 courses of oblimersen at doses of 3, 5, or 7 mg/kg/d given as a 7 day CIVI in combination with 4 or 5 day CIVI of 5-FU (1000 or 750 mg/m2/d) plus intravenous cisplatin (100 or 75 mg/m2 over 2 hours). The recommended phase II dose of oblimersen was 5 mg/kg/d in combination with 5-FU (750 mg/m2/d for 4 days) and cisplatin (75 mg/m). The most common grade 3 to 4 adverse events that occurred in at least 10% of patients at all dose levels included neutropenia (33%), hypokalemia (27%), infection (20%), and mucositis, fatigue, dizziness, thrombosis, and dehydration (in 13% for each category). CONCLUSION: The combination of oblimersen with 5-FU and cisplatin chemotherapy is feasible in patients with advanced upper gastrointestinal cancer, with antitumor activity observed in gastric carcinoma.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: K N Chi; M E Gleave; R Klasa; N Murray; C Bryce; D E Lopes de Menezes; S D'Aloisio; A W Tolcher Journal: Clin Cancer Res Date: 2001-12 Impact factor: 12.531
Authors: Michael J Morris; William P Tong; Carlos Cordon-Cardo; Marija Drobnjak; William K Kelly; Susan F Slovin; Kathryn L Terry; Karen Siedlecki; Paul Swanson; Mohmed Rafi; Robert S DiPaola; Neal Rosen; Howard I Scher Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Maryla Krajewska; Shinichi Kitada; Jane N Winter; Daina Variakojis; Alan Lichtenstein; Dayong Zhai; Michael Cuddy; Xianshu Huang; Frederic Luciano; Cheryl H Baker; Hoguen Kim; Eunah Shin; Susan Kennedy; Allen H Olson; Andrzej Badzio; Jacek Jassem; Ivo Meinhold-Heerlein; Michael J Duffy; Aaron D Schimmer; Ming Tsao; Ewan Brown; Anne Sawyers; Michael Andreeff; Dan Mercola; Stan Krajewski; John C Reed Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: C M Rudin; G A Otterson; A M Mauer; M A Villalona-Calero; R Tomek; B Prange; C M George; L Szeto; E E Vokes Journal: Ann Oncol Date: 2002-04 Impact factor: 32.976
Authors: Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu Journal: Am J Cancer Res Date: 2010-09-30 Impact factor: 6.166